Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.53 |
| ▸ | THRA | P10827 | 5/20 | 0.53 |
| ▸ | THRB | P10828 | 5/20 | 0.53 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | ASPH | Q12797 | 1/20 | 0.53 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.53 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.52 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230004 | 0.93 | HIF1A (0.56) | HIF1AEGLN1THRATHRB | |
| SCHEMBL11934015 | 0.88 | HIF1A (0.53) | HIF1AEGLN1THRATHRBBBOX1 | |
| SCHEMBL2761626 | 0.86 | MAOB (0.57) | MAP1LC3BMAP1LC3A | |
| SCHEMBL2761574 | 0.86 | HIF1A (0.53) | HIF1ATHRATHRB | |
| SCHEMBL934454 | 0.83 | — | — | |
| SCHEMBL2761685 | 0.82 | HIF1A (0.47) | HIF1AEGLN1 | |
| SCHEMBL2761489 | 0.82 | CA12 (0.58) | EGLN1 | |
| SCHEMBL10009619 | 0.81 | HIF1A (0.53) | HIF1A | |
| SCHEMBL2761719 | 0.80 | EGLN1 (0.46) | EGLN1 | |
| SCHEMBL2761386 | 0.80 | EGLN1 (0.58) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| EP-2454249-B1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO LTD (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| WO-2011006355-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | BEIJING BETA PHARMA INC. (CN) | 2011-01-20 | — | — | WO | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885EGLN1 5/4885THRA 1962/4885 |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | HIF1AN, HIF1A, EGLN3 | HIF1A 2/4885EGLN1 5/4885THRA 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.